These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 25702621)

  • 1. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma.
    Raleigh DR; Algazi A; Arron ST; Neuhaus IM; Yom SS
    Br J Dermatol; 2015 Aug; 173(2):544-6. PubMed ID: 25702621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
    Ali FR; Lear JT
    Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
    Meani RE; Lim SW; Chang AL; Kelly JW
    Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
    Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA
    Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
    JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
    Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
    JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma.
    Wilkes GM
    Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):31-3. PubMed ID: 25375009
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
    Mathis J; Doerr T; Lin E; Ibrahim SF
    Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
    Sobanko JF; Okman J; Miller C
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vismodegib.
    Meiss F; Zeiser R
    Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
    Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
    Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vismodegib in the treatment of advanced BCC.
    O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
    Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.